Acotec Scientific Holdings Limited announced that on April 18, 2023, the Company received the registration approval from the PRC National Medical Products Administration for ACOART AVENS, a paclitaxel coated high-pressure balloon, which used in percutaneous transluminal angioplasty ("PTA") for treating arteriovenous fistula ("AVF") stenosis of hemodialysis patients. The company has improved the product design, optimized coating technology and applied new material to enhance the treatment effect and ease of operation. The company will carry out marketing activities in PRC market when appropriate.
Acotec Scientific Holdings Limited
Equities
6669
KYG0096M1096
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.47 HKD | 0.00% | -7.20% | -33.78% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-33.78% | 305M | |
+75.67% | 12.57B | |
-21.78% | 7.43B | |
-6.25% | 5.79B | |
+8.16% | 5.09B | |
-17.37% | 4.78B | |
+16.22% | 4.2B | |
-15.15% | 4.13B | |
-10.69% | 3.19B | |
-1.98% | 2B |
- Stock Market
- Equities
- 6669 Stock
- News Acotec Scientific Holdings Limited
- Acotec Scientific Holdings Limited Announces Approval for Acotec Scientific Holdings Limited by the PRC National Medical Products Administration